Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 21, 2009

Exact Sciences Fortifies Position in Stool-Based DNA Detection Through Deal with Hologic

  • Exact Sciences obtained a worldwide license for Hologic’s Invader, Invader plus, and real-time Invader detection chemistries for use in colorectal cancer screening. The Invader chemistry is an accurate, easy-to-use, and rapid molecular detection platform that can be combined with PCR, according to Hologic. Exact anticipates coupling the digital PCR technology it has exclusively licensed from Johns Hopkins University with the quantitative detection capabilities of the Invader chemistry.

    Exact states that this deal reinforces its stronghold in the stool-based DNA, or sDNA, screening market. The company’s IP portfolio now includes exclusive licenses to key detection technologies, sDNA testing methods, and important biomarkers, it adds.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »